Combinación de metformina frente a inhibidores de la dipeptidilpeptidasa y sulfonilureas en el tratamiento de la diabetes tipo 2

logistic regression and ANCOVA models. Results. 1,405 patients were recruited (average age 67.1 years old; 56.2% male). 37.0% started a second treatment with DPP-4 inhibitors, and 63.0% with sulfonylureas. After two years of follow up, patients treated with DPP-4 inhibitors showed greater treatment adherence (70.3% vs. 60.6%; p <0.001); better metabolic control (64.3% vs. 60.6%; p<0.001), and a lower proportion of hypoglycemia (13.9% vs. 40.4%; p <0.001, respectively). The average/unit of adjusted total costs was 2,341 vs. 2,512; p = 0.038. CVE and renal failure rates were 3.7% vs. 6.4%; p = 0.027. Vildagliptin was the most used drug among DPP-4 inhibitors. Conclusions. Sulfonylureas were the most used drug for diabetes treatment. Patients treated with DPP-4 inhibitors had higher adherence and control of diabetes, with lower rates of hypoglycemia and CVE, resulting in lower healthcare costs

Diabetes mellitus · Hypoglycemia · Insulin · Metabolic control analysis · Metformin · Sulfonylurea · Type 2 diabetes · Vildagliptin · Diabetes Management and Research · Diabetes Treatment and Management · Medication Adherence and Compliance · Medicine · Endocrinology · Internal Medicine

• A new method of classifying prognostic comorbidity in longitudinal studies

  Open Access•Mary E Charlson, Peter Pompei et al.•Journal of Chronic Diseases•1987

  Add to list